BY Capital GmbH Co. KG — Full Portfolio
3 tracked investments · listed companies and verified rows first
Dover, US
Board seatJason Whitmire· per SEC Form D · $572.7K raise · filed Jan 2026
Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue.
AI & Machine LearningBiotechDeep TechTolland, US
John Deacon(Executive Officer, Director)Colin J. Foster(Executive Officer, Director)
BoardAlex Brunicki(Director)
Board seatJason Whitmire· per SEC Form D · $6.6M raise · filed Jun 2023
Co-investorsBackedBlueYard Capital
SEEQC develops a digital quantum computing platform that integrates the core functions of a quantum computer—including qubits and classical control logic—onto superconducting cryogenic chips, aiming to scale qubits without added complexity.
Deep TechQuantum ComputingSemiconductorsElmsford, US
Oleg Mukhanov(CSO)John Levy(CEO)Raja Bal(CFO)Tim Anglim(Executive Officer)Matthew Hutchings(Executive Officer)Shu-Jen Han(CTO)
Board seatJason Whitmire· per SEC Form D · $25M raise · filed Jan 2026
Co-investorsBlueYard CapitalNordicNinjaEQT VenturesArcTern VenturesBooz Allen VenturesCambium Capital+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.